CytoDyn Inc. CYDY
0.23 USD -0.01 (-2.92%)
Nov 10, 2026, 3:52 PM EST
0.23 Day range 0.24
0.18 52-week range 0.40
- YTD
- -16.79%
- 1 year
- -6.80%
News
globenewswire.com CytoDyn and QLHC Advance Leronlimab into Two New PRE-I-SPY Studies in Metastatic Triple-Negative Breast Cancer VANCOUVER, Washington, Nov. 10, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized…
defenseworld.net CytoDyn (OTCMKTS:CYDY) Shares Break Below Two Hundred Day Moving Average – Here’s What Happened Shares of CytoDyn Inc. (OTCMKTS:CYDY - Get Free Report) passed below its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of $0.25 and traded as…
globenewswire.com CytoDyn Presents Updated Leronlimab Data in Metastatic Colorectal Cancer at ESMO Congress 2026 VANCOUVER, Washington, Oct. 26, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized…
seekingalpha.com CytoDyn Inc. (CYDY) Discusses Latest Scientific, Clinical, Operational, and Financial Progress and Upcoming Priorities Transcript CytoDyn Inc. (CYDY) Discusses Latest Scientific, Clinical, Operational, and Financial Progress and Upcoming Priorities Transcript
marketbeat.com CytoDyn Highlights Early CLOVER Data, Names Robert Hoffman CEO CytoDyn OTCMKTS: CYDY provided an update on its Phase II CLOVER study of leronlimab in metastatic colorectal cancer, highlighting early circulating tumor DNA, or ctDNA, data, preliminary clinical…
globenewswire.com CytoDyn Appoints Robert E. Hoffman as Chief Executive Officer Dr. Jacob Lalezari to remain with Company in scientific innovation and discovery role VANCOUVER, Washington, Oct. 19, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"),…
globenewswire.com CytoDyn to Host Investor Webcast VANCOUVER, Wash., Oct. 15, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized…
globenewswire.com CytoDyn to Present Updated Data from Phase 2 CLOVER Clinical Study at ESMO Congress 2026 VANCOUVER, Washington, Oct. 08, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized…
marketbeat.com CytoDyn Highlights CLOVER Progress, Early ctDNA Declines in Colorectal Cancer CytoDyn OTCMKTS: CYDY Chief Financial Officer Robert E. Hoffman outlined the company's clinical-development plans for leronlimab, a CCR5-targeting humanized monoclonal antibody being studied in…
defenseworld.net CytoDyn (OTCMKTS:CYDY) Stock Price Crosses Below Fifty Day Moving Average – Here’s Why CytoDyn Inc. (OTCMKTS:CYDY - Get Free Report) shares crossed below its 50 day moving average during trading on Thursday. The stock has a 50 day moving average of $0.21 and traded as low as $0.1952.…
globenewswire.com CytoDyn Inc. to Present at the Life Sciences Investor Forum on September 17th VANCOUVER, Wash., Sept. 15, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized…
globenewswire.com CytoDyn Closes $16.5 Million Financing to Fund Continued Development of Leronlimab VANCOUVER, Washington, Sept. 01, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized…
prnewswire.com Kessler Topaz Meltzer & Check, LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of CytoDyn Inc. common stock TACOMA, Wash., July 22, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP announces proposed class action settlement on behalf of purchasers of CytoDyn Inc. common stock between March 27, 2020…
globenewswire.com CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer's Disease Phase 2a study will evaluate the safety and biological activity of leronlimab in patients over the age of 50 with early-stage, biomarker-confirmed Alzheimer's disease VANCOUVER, Washington, June 11,…
globenewswire.com CytoDyn to Present at the LD Micro Invitational XVI CFO Robert E. Hoffman to deliver company presentation on May 18 at 10 a.m.
seekingalpha.com CytoDyn Inc. (CYDY) Discusses Corporate and Clinical Update With Focus on Leronlimab Development and Recent Financing Transcript CytoDyn Inc. (CYDY) Discusses Corporate and Clinical Update With Focus on Leronlimab Development and Recent Financing Transcript
globenewswire.com CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer Program provides access to leronlimab for patients with limited treatment options while supporting ongoing clinical development
globenewswire.com CytoDyn to Host Investor Webcast VANCOUVER, Washington, April 23, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized…
globenewswire.com CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 Ongoing Phase 2 study in metastatic colorectal cancer (mCRC) demonstrates early clinical and biomarker activity with leronlimab in combination with TAS-102 and bevacizumab, supporting CCR5 as a…
globenewswire.com CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study Enrollment concludes with just over 60 patients participating across seven clinical sites located throughout the United States
benzinga.com Stocks That Hit 52-Week Highs On Tuesday 
benzinga.com Stocks That Hit 52-Week Highs On Thursday 
benzinga.com Stocks That Hit 52-Week Highs On Wednesday 
benzinga.com Stocks That Hit 52-Week Highs On Tuesday 
benzinga.com Stocks That Hit 52-Week Highs On Friday - benzinga.com 3 Ways To Profit From Merger Activity In The Pharmaceutical Sector